TY-JUR T1 - 人类肺部修复潜在治疗靶标免疫体内肺灌注JF - 欧洲呼吸期刊JO - EUR RESPIR J DO - 10.1183 / 13993003.02222-2019 SP - 1902222 AU - Wong，AARON AU - Zamel，Ricardo Au - Yeung，Jonathan Au - 獾，Gary D. Au - Dos Santos，Claudia C. Au - Bai，Xiaohui Au - Wang，Yubo Au - Keshavjee，Shaf Au - Liu，Mingyao Y1 - 2020 / 01/01 UR - http：//Erj.ersjournals.com/content/early/2020/02/26/13993003.02222-2019.Abstract n2 - 简介EXVivo肺灌注（EVLP）技术已经开发出来评估边缘供体肺的功能，这些肺部有显着增加的供体肺利用率。EVLP还通过损伤特异性治疗等抗生素或纤维蛋白溶解剂如抗生素或纤维蛋白溶解剂探索的平台。我们假设移植和EVLP之间的积极表达途径可以揭示移植前肺部修复损伤和潜在治疗靶标的常见机制。材料和方法通过“脑死后捐赠捐赠”肺部的外周组织活组织检查进行回顾性转录组科分析，使用46前/后移植后对和49个前/后EVLP对。途径分析用于鉴定和比较供体肺部对移植和EVLP的反应。结果二十一条途径主要在移植中富集，包括淋巴细胞活化和细胞死亡的上调，以及代谢和蛋白质合成的下调。七种途径主要在EVLP中富集，包括下调白细胞功能和血管过程的上调。通常富集二十三种途径，包括激活先天炎症，细胞死亡，热应激和代谢下调。在炎症簇中，TLR / MYD88信令具有最多的节点，并且炎症是炎症的核心。 These mechanisms have been previously speculated as major mechanisms of acute lung injury in animal models.Conclusion EVLP and transplantation share common molecular features of injury including innate inflammation and cell death. Blocking these pathways during EVLP may allow for lung repair prior to transplantation.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Wong has nothing to disclose.Conflict of interest: Dr. Zamel has nothing to disclose.Conflict of interest: Dr. Yeung has nothing to disclose.Conflict of interest: Dr. Bader has nothing to disclose.Conflict of interest: Dr. Dos Santos has nothing to disclose.Conflict of interest: Dr. Bai has nothing to disclose.Conflict of interest: Dr. Wang has nothing to disclose.Conflict of interest: Dr. Keshavjee has nothing to disclose.Conflict of interest: Dr. Liu has nothing to disclose. ER -